

Application No.: 10/581,140
Filing Date: May 30, 2007
Applicants: Joseph D. Buxbaum and Nicolas Ramoz

Remarks

Claims 1-23 were pending in the subject application. By this amendment, Claim 1 has been amended to further clarify applicants' invention, and Claims 4-23 have been canceled without prejudice or disclaimer's to applicants' right to pursue prosecution of these claims in a later-filed continuation or divisional application. The specification also has been amended at page 1 to correct the information concerning governmental support. The amendments to Claim 1 and the specification do not introduce new matter. Accordingly, entry of the preceding amendments is respectfully requested.


In response to the restriction requirement set forth in the Office Action, applicants hereby elect, with traverse, to prosecute Group II, Claims 1-3 (in part as it reads on rs2292813). However, applicants submit that it would not be an undue burden on the Examiner to also consider Group I, Claims 1-3 (in part as it reads on rs2056202), and Group III, Claims 1-3 (in part as it reads on rs2292813 and rs2056202), since a search in the art for polymorphism sites of the SLC25A12 gene would necessarily find art that would be relevant to rs2292813 and rs2056202. Therefore, it would not be an undue burden on the Examiner to consider Groups I-III in the current application.

No fee, other than the \$65 one month extension of time fee, is deemed necessary in connection with the filing of this Amendment. However, if this fee is in any way deficient, or if any additional fee is required to preserve the pendency of the subject application, authorization is hereby given to charge any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicants
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: New York, New York
June 17, 2009

By: 
Craig J. Arnold, Reg. No. 34,287